Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Clare Grieve"'
Autor:
Anita Kumar, Carla Casulo, Erel Joffe, Craig Moskowitz, John Gerecitano, Alison Moskowitz, Anas Younes, Pamela Drullinsky, Esther Drill, Morgan Choma, Clare Grieve, Ashlee Joseph, Leana Laraque, Dylan Schick, Andrew Zelenetz, Paul Hamlin
Publikováno v:
Leukemia & Lymphoma. 63:2889-2896
This study evaluated ofatumumab (Ofa), an anti-CD20 monoclonal antibody, alone or with bendamustine (Benda), in transplant-ineligible patients with mantle cell lymphoma. Low-risk patients received Ofa monotherapy. Non-responders received subsequent t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76e4afc2392b9212d162e253bd5f0359
https://doi.org/10.1080/10428194.2022.2109155
https://doi.org/10.1080/10428194.2022.2109155
Autor:
Robert Stuver, Laure Michaud, Carla Casulo, Ranjana H. Advani, Elizabeth L. Budde, Paul M. Barr, Connie Lee Batlevi, Philip C Caron, Louis S. Constine, Savita Dandapani, Pamela Drullinsky, Jonathan W. Friedberg, Clare Grieve, Audrey Hamilton, Paul A. Hamlin, Richard Hoppe, Steven M. Horwitz, Niloufer Khan, Matthew J. Matasar, Ariela Noy, M.Lia Palomba, Heiko Schoder, David J. Straus, Shreya Vemuri, Joachim Yahalom, Joanna C. Yang, Anas Younes, Andrew D. Zelenetz, Craig H. Moskowitz, Anita Kumar, Alison J. Moskowitz
Publikováno v:
Blood. 140:1756-1758
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a34867e3c7e460510329f9765b29d1f
https://doi.org/10.1182/blood-2022-156382
https://doi.org/10.1182/blood-2022-156382
Autor:
Colette Owens, Allison P. Jacob, Jade Ruiters, Sidney Sechio, Audrey Hamilton, Clare Grieve, Puja Chadha, Mikhail Roshal, Tak Takvorian, Daneal Portman, Anthony R. Mato, Krista J Scorsune, Jason Carter, Ahmet Dogan, Lauren Ramos, Ai Ni, Natascha Nolet, Juliana M.L. Biondo, Jane Huang, Ephraim P. Hochberg, Anita Kumar, Stephanie Hughes, Morgan Choma, M. Lia Palomba, Rosalba Martignetti, Ariela Noy, Jeffrey A. Barnes, Meghan C. Thompson, P. Connor Johnson, Jeremy S. Abramson, Connie Lee Batlevi, Julia M Lynch, Qun Wu, Chaya Friedman, Erel Joffe, Joanna Mi, Brianne McGree, Elizabeth Simkins, Venkatraman E. Seshan, Matthew J. Matasar, Kelsey Flaherty, Omar Abdel-Wahab, Lindsey E. Roeker, Andrew D. Zelenetz, Jacob D. Soumerai, Neena Mahajan
Publikováno v:
The Lancet Haematology. 8:e879-e890
Summary Background We hypothesised that combining zanubrutinib with obinutuzumab and venetoclax (BOVen) as an initial therapy for chronic lymphocytic leukaemia and small lymphocytic lymphoma would lead to high rates of undetectable minimal residual d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdf7327afd36fee111882d955455bfdf
https://doi.org/10.1016/s2352-3026(21)00307-0
https://doi.org/10.1016/s2352-3026(21)00307-0
Autor:
Steven M. Horwitz, Philip Caron, Pamela Drullinsky, Joachim Yahalom, Matthew J. Matasar, Connie Lee Batlevi, Anita Kumar, Esther Drill, A. Joseph, Audrey Hamilton, Ranjana H. Advani, Richard T. Hoppe, Heiko Schöder, Jonathan W. Friedberg, Joanna C. Yang, Elizabeth Budde, Paul A. Hamlin, Louis S. Constine, Maria Lia Palomba, Craig H. Moskowitz, Anas Younes, Shreya Vemuri, Andrew D. Zelenetz, Niloufer Khan, Clare Grieve, David J. Straus, Carla Casulo, Leana Laraque, Alison J. Moskowitz, Paul M. Barr, Ariela Noy, S.V. Dandapani
Publikováno v:
Journal of Clinical Oncology. 39:2257-2265
PURPOSE To improve curability and limit long-term adverse effects for newly diagnosed early-stage (ES), unfavorable-risk Hodgkin lymphoma. METHODS In this multicenter study with four sequential cohorts, patients received four cycles of brentuximab ve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b3e9430e90e7407e98451d8866a6b16
https://doi.org/10.1200/jco.21.00108
https://doi.org/10.1200/jco.21.00108
Autor:
Ely Hahami, Clare Grieve
Publikováno v:
Journal of Student Research. 11
An essential element of the American dream is owning a home in the neighborhood of one’s choice. But what happens when banks discriminate against minorities and consequently undermine fair mortgage lending laws? The implications cannot be understat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::06467bb5a016e99da4289e83d42a2ff4
https://doi.org/10.47611/jsrhs.v11i3.2854
https://doi.org/10.47611/jsrhs.v11i3.2854
Autor:
Pamela Drullinsky, Anita Kumar, Neena Mahajan, Connie W. Batlevi, Andrew D. Zelenetz, A. Joseph, Paul A. Hamlin, Clare Grieve, Leana Laraque, David J. Straus, M. Matasar
Publikováno v:
Hematological Oncology. 39
Introduction: Bendamustine (B) and rituximab (R) with ibrutinib (IBR) was well-tolerated and efficacious (Maddocks Blood 2015). Ibrutinib and venetoclax (VEN) were synergistic and active in relapsed, refractory (R/R) MCL (Tam NEJM 2018). VEN increase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a1fe468e8fd3c83752a67b3d5753ee3
https://doi.org/10.1002/hon.88_2881
https://doi.org/10.1002/hon.88_2881
Autor:
Jeffrey A. Barnes, Jenny Wu, Anita A Kumar, Krista J Scorsune, Allison P. Jacob, Jade Ruiters, Connie Lee Batlevi, Rosalba Martignetti, Chaya Friedman, Venkatraman E. Seshan, Daneal Portman, Audrey Hamilton, Ai Ni, Anthony R. Mato, Morgan Choma, Meghan C. Thompson, Clare Grieve, Jane Huang, Elizabeth Simkins, Ahmet Dogan, Tak Takvorian, Jason Carter, Brianne McGree, Colette Owens, Julia M Lynch, Ariela Noy, Puja Chadha, Sidney Sechio, Mikhail Roshal, Erel Joffe, Joanna Mi, M. Lia Palomba, Kelsey Flaherty, Lindsey E. Roeker, Natascha Nolet, Andrew D. Zelenetz, Stephanie Hughes, P. Connor Johnson, Matthew J. Matasar, Omar Abdel-Wahab, Jacob D. Soumerai, Juliana M.L. Biondo, Neena Mahajan, Ephraim P. Hochberg, Jeremy S. Abramson
Publikováno v:
Blood. 138:3753-3753
Background: Venetoclax (Ven; BH3 mimetic) and Obinutuzumab (O; CD20 antibody) is an approved, fixed-duration regimen (one year) that induces undetectable minimum residual disease (uMRD) and durable remissions in treatment naïve patients (pts) with c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d7655bd9ce25ab3178eacf658c568de1
https://doi.org/10.1182/blood-2021-150961
https://doi.org/10.1182/blood-2021-150961
Autor:
Anita Kumar, Jacob D. Soumerai, Jeremy S. Abramson, Connie Lee Batlevi, Puja Chadha, Ahmet Dogan, Lorenzo Falchi, Kelsey Flaherty, Chaya Friedman, Clare Grieve, Caleb Ho, P. Connor Johnson, Ashlee Joseph, Niloufer Khan, Joanna Mi, Rosalba Martignetti, Matthew J. Matasar, Colette Owens, Jade Ruiters, Sidney Sechio, Venkatraman Seshan, Elizabeth Simkins, Omar Abdel-Wahab, Andrew D. Zelenetz
Publikováno v:
Blood. 138:3540-3540
Background: TP53 mutant mantle cell lymphoma (MCL) is associated with poor survival outcomes with chemoimmunotherapy (Eskelund Blood 2017) and there is no standard frontline treatment for this high-risk patient population. The combination of Bruton's
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::952d2b1a0bb259448ab2df4d531d4d21
https://doi.org/10.1182/blood-2021-151831
https://doi.org/10.1182/blood-2021-151831
Autor:
Clare Grieve, Tania Veliz Rodriguez, Shreya Vemuri, Andrew D. Zelenetz, Leana Laraque, Devin Copley, Jason R. Westin, Stephen J. Schuster, Chelsea D. Mullins, Ellen Napier, Venkatraman E. Seshan, Gita Masand, Allison P. Jacob, A. Joseph, Grzegorz S. Nowakowski, Anita A Kumar, Izidore S. Lossos
Publikováno v:
Blood. 138:52-52
Background: Diffuse large B-cell lymphoma (DLBCL) is frequently curable after frontline therapy, however, relapses can occur after achievement of a PET-negative complete remission (CR). Early detection of relapse may be associated with improved outco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b7d5af2752067df9f0c6b209162b4f50
https://doi.org/10.1182/blood-2021-150572
https://doi.org/10.1182/blood-2021-150572
Autor:
Heiko Schöder, Paul A. Hamlin, Joachim Yahalom, Matthew J. Matasar, Lihua E. Budde, Alison J. Moskowitz, Maria Lia Palomba, Shreya Vemuri, Susan J. McCall, Carla Casulo, Anas Younes, Andrew D. Zelenetz, Paul M. Barr, Richard T. Hoppe, Audrey Hamilton, Craig H. Moskowitz, Ranjana H. Advani, Anita A Kumar, Connie Lee Batlevi, Pamela Drullinsky, S.V. Dandapani, Esther Drill, Steven M. Horwitz, Ariela Noy, Louis S. Constine, Philip Caron, Clare Grieve, David J. Straus, Jonathan W. Friedberg, Joanna C. Yang
Publikováno v:
Blood. 134:2834-2834
Introduction: The standard therapy for early stage, unfavorable risk Hodgkin lymphoma (HL) with disease bulk is combined modality therapy, typically 4-6 cycles of ABVD followed by 30Gy involved-site radiotherapy (ISRT) (Eich JCO 2010). In this pilot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::38e037a497c6c68526ddbfc332e07bd9
https://doi.org/10.1182/blood-2019-123150
https://doi.org/10.1182/blood-2019-123150